Capsule Summary Slides

Share

Program Content

Activities

  • PHERGain
    PHERGain: 3-Yr iDFS Results From the Phase II Trial of Chemotherapy De‑escalation in HER2+ Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2023

  • NATALEE
    NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor vs Nonsteroidal Aromatase Inhibitor Alone for HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2023

  • SOFT: Prognostic/Predictive Analyses
    Evaluation of the Prognostic and Predictive Value of PAM50 Intrinsic Subtypes and ROR Scores in Premenopausal Women With HR+/HER2- Early Breast Cancer Enrolled in the SOFT Trial
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2023

  • T-DXd Efficacy/Safety: Age Analysis
    Pooled Analysis of Trastuzumab Deruxtecan Efficacy and Safety by Age in Patients With HER2+ Metastatic Breast Cancer From DESTINY-Breast01, 02, and 03 Trials
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2023

  • monarchE Subgroup Analysis by Age
    monarchE Subgroup Analysis by Age: Adjuvant Abemaciclib + ET in Older vs Younger Patients With High-Risk, Node-Positive HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2023

  • Ovarian Ablation/Suppression in BC
    EBCTCG Meta-analysis of Breast Cancer Recurrence and Survival Following Ovarian Ablation or Suppression in Premenopausal Women
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • SONIA
    SONIA: Phase III Trial Assessing the Optimal Therapeutic Position of CDK4/6 Inhibitors for Patients With HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • HER3-DXd in HER2- Breast Cancer
    Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HER2-Negative Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • PALMIRA
    Phase II PALMIRA: Second-line ET ± Palbociclib Maintenance in Patients With HR+/HER2- Advanced Breast Cancer After Clinical Benefit on First-line Palbociclib + ET
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • TROPiCS-02 Final Analysis
    TROPiCS-02: Final OS Analysis of the Phase III Trial of Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2023

  • PADA-1 Update
    Phase III PADA-1 Update: Palbociclib + Switching to Fulvestrant vs Continuing AI Therapy in ER+/HER2- MBC With Rising ESR1 Mutations by ctDNA Analysis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.